林业发展局批准Revuforj治疗各年龄段病人的特定急性白血病病例。 FDA approves Revuforj for treating specific acute leukemia cases in patients of all ages.

林业发展局批准了Revuforj(revumenib),这是治疗KMT2A基因转移的病人,包括成人和1岁及1岁以上儿童的复发性或耐寒性急性白血病的第一位抑制剂。 The FDA has approved Revuforj (revumenib), the first menin inhibitor for treating relapsed or refractory acute leukemia in patients with a KMT2A gene translocation, including adults and children aged one year and older. 根据AUGOT-101号试验,Revuforj显示21.2%的完全恢复率,中位答复期为6.4个月。 Based on the AUGMENT-101 trial, Revuforj showed a 21.2% complete remission rate with a median response duration of 6.4 months. 常见副作用包括出血、恶心和磷酸盐含量升高。 Common side effects include hemorrhage, nausea, and increased phosphate levels.